EATONTOWN, NJ, November 8, 2022 – Clinilabs Drug Development Corporation (“Clinilabs”), a leading global, full-service CNS CRO, today announced that Dr. Jeff Mulchahey has joined the company as Chief Development Officer (CDO). Dr. Mulchahey will continue to expand Clinilabs’ presence as a global leader in the management of phase 2 and 3 CNS clinical trials, [...]
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, and its partner Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced that the U.S. Drug Enforcement Agency (“DEA”) has granted a Schedule I license to [...]
EATONTOWN, N.J.--(BUSINESS WIRE)--Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, announced today that enrollment has begun in a Phase 1/2a clinical trial of CYB003, the first novel psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder (“MDD”). [...]
